| | | Dufour et al. [12] | Çankaya et al. [13] | Nayak et al. [14] | Sood et al. [15] | Lee et al. [16] | Cai et al. [21] | Lai et al. [17] | Ahmad et al. [18] | Jung et al. [19] | Ingale et al. [20] | Zhou et al. [22] | Dagna et al. [11] | Lee et al. [23] | Jo et al. (this study) |
| | No. of patient | 1 | 1/3 cases | 1 | 1 | 1 | 4 | 1 | 1 | 1 | 1 | 1/17 cases | 1 | 1/9 cases | 1 |
| | Age (year) | 8 | 17 | 24 | 27 | 37 | 69.5 (58–84) | 51 | 7 | 25 | 4 | 25 | 65 | 60 | 62 |
| | Sex | M | F | F | M | M | M (1) F (3) | F | M | F | M | M | F | F | M |
| | Preexisting disease | No | No | No | No | No | MDS (2) MPN (2) | AML—allo-HSCT | No | No | No | N/M | MDS– allo-HSCT | N/M | No |
| | Lesion sites | Parotid | Parotid (R) | Parotid (B) | Facial nerve palsy | Neck mass (L) | Parotid (R) Pleura | SMG (R) | Parotid (L) | SMG (R) | Parotid (R) Mandible | Parotid | SMG (R) | SMG (L) | Parotid | | Facial nerve palsy | Skin | Nasal cavity | Parotid | =>3 M after Rec neck mass and parotid (L) | Parotid (L) | Gingiva | Ptosis (B) | | Masseteric space | SMG | | LN in neck (L) | LN in neck (L) | | Paravertebral region | Hepatosplenomegaly | LN in neck | SMG (L) skin | Masseter muscle (R) | Nasopharynx, intracranial | Skull base | LN | | Orbit | SMG (R) | Retroorbital | Nasopharynx and PNS |
| | Imaging study | MRI | | | | CT | | PET-CT | CT | CT | CT | | CT | | CT, MRI, PET-CT |
| | US-FNA/CNB | | FNA (blast) | FNA (atypical cells) | FNA (blast) | Not performed | FNA flow cytometry | FNA (nondiagnostic) | FNA (nondiagnostic) | FNA (nondiagnostic) | | | FNA (nondiagnostic) | | CNB (malignant parotid) | | Immature cell (3) | CNB (MS) | | Blast (1) |
| | Surgery | | | LN surgical biopsy | | Gross total resection | | Excision of SMG (R) | | Excision of SMG (R) | Surgical biopsy | Excision of SMG, parotid, LN | | Excision of SMG (L) | Total parotidectomy, neck dissection |
| | PBS | BM (AML) | BM (AML) | PBS (N) | PBS (blast) | PBS (N) BM (N) | N/M | BM (N) | BM (AML) | N/M | PBS (blast) | N/M | PBS (N) | N/M | PBS (N) | | BM analysis | BM (AML) | BM (AML) | => BM (AML) | BM (AML) | BM (N) | BM (AML) |
| | Diagnosis | MS with BM involvement | MS with BM involvement | MS with BM involvement | MS with PB/BM involvement | Isolated MS
=> MS with BM involvement, 3 M after | Progression of MDS (2) /MPN (2) | Relapse of AML (allo-HSCT) | MS with BM involvement | Primary MS (BM N/M) | MS with PB/BM involvement | MS (N/M) | Relapse of AML (allo-HSCT) | MS (N/M) | MS with BM involvement |
| | AML type | AML-M2, t (8; 21) | AML-M4 | AML-M2 with t (8; 21) | AML-M5 | N/M | MDS (2)/CMML (2) | AML-M2 | AML-M2 | N/M | AML with t (8; 21) | N/M | AML-M4 | N/M | MDS-EB |
| | Treatment | CTx (cytarabine, daunorubicin) | Induction CTx for AML (None specified) | CTx (arabinoside, Adriamycin) | CTx (cytarabine, daunorubicin) | Induction CTx (none specified) | N/M | Salvage CTx (mitoxantrone, etoposide) + RTx (1000 cGy) | Induction CTx (Cytosar, daunorubicin, etoposide) | N/M | N/M | CTx (none specified) | CTx (none specified) | CTx (none specified) | Induction CTx (arabinoside, idarubicin) |
| | Outcomes | Died | Died | Died | N/M | N/M | N/M | Died | F/U loss | N/M | N/M | N/M | N/M | Alive | Alive |
|
|
AML, acute myeloid leukemia; AML type, AML type according to published studies; AML-M2, AML-M4, and AML-M5, French-American-British classification-type; allo-HSCT, allogeneic hematopoietic stem-cell transplantation; BM, bone marrow; CMML, chronic myelomonocytic leukemia; CTx, chemotherapy; FNA, fine needle aspiration; LN, lymph nodes; MDS, myelodysplastic syndrome; MPN, myeloproliferative neoplasms; N, no pathologic results; PBS, peripheral blood smear; PNS, paranasal sinuses; Rec, recurrence; RTx, radiotherapy; SMG, submandibular gland; M, month; B, both; L, left; R, right; N/M, not mentioned.
|
